PM
URGN icon

Prosight Management’s UroGen Pharma URGN Stock Holding History

Prosight Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-146,179
Closed -$2.61M – 64
2020
Q1 		$2.61M Sell
146,179
-71,507
-33% -$1.93M 1.22% 25
2019
Q4 		$7.26M Sell
217,686
-107,699
-33% -$2.94M 3.19% 14
2019
Q3 		$7.75M Buy
325,385
+64,457
+25% +$2.11M 4.3% 7
2019
Q2 		$9.38M Buy
260,928
+103,066
+65% +$3.8M 4.73% 9
2019
Q1 		$5.83M Buy
+157,862
New +$6.62M 2.55% 14

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

Prosight Management's URGN Position: Q2 2020 in Review

Prosight Management sold out of UroGen Pharma (URGN) in Q2 2020, closing a stake of 146,179 shares — an estimated $2.61M sold.

Prosight Management first reported a position in URGN in Q1 2019 and held it in 5 quarters. The position peaked at $9.38M in Q2 2019. 84 funds tracked by Wall St. Rank hold URGN as of Q2 2020.

  • Prosight Management reported no remaining UroGen Pharma position as of Q2 2020 after selling out during the quarter.
  • Prosight Management sold 146,179 UroGen Pharma shares in Q2 2020, an estimated $2.61M.
  • Prosight Management first reported a position in UroGen Pharma in Q1 2019 and held it in 5 quarters.
  • Prosight Management's UroGen Pharma position peaked at $9.38M in Q2 2019.
  • 84 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2020.

Based on Prosight Management's 13F filing for Q2 2020, filed 14 Aug 2020.